Fig 1.
The differences between 8-week-old K14-VEGF mice and WT mice.
(a) Appearance differences between WT mice (left) and K14-VEGF mice (right). (b) H&E staining of the ear of WT mice (left) and K14-VEGF mice (right). A representative of six mice from three independent experiments is shown. (c) IHC analysis of CD31-positive cells in WT mice (left) and K14-VEGF mice (right). Images are representative of five mice from three independent experiments in each group. Arrows indicate the location of the CD31+ cells. Scale bars, 50 μm. (d) The GO analysis of K14-VEGF mice compared with wild type mice, n = 3.
Fig 2.
IMQ-treated K14 mice had more stable skin inflammation.
(a) The thickness of the ear was measured on the days indicated (Mean±SD; n = 5 mice for each time point in each group). (b) Erythema, scaling and thickness of ear skin was assessed on the indicated days with a scale from 0 to 4. The cumulative score is presented (Mean±SD; n = 5 mice for each time point in each group). (c) H&E staining of the mouse ear skin of the treatment groups (200×). (d) Rate of epidermal proliferation in different time after appalication of IMQ.
Fig 3.
IMQ induced a longer skin inflammation period.
(a) mRNA expression of some pro-inflammatory cytokines in the mice skin, n = 6. (b) IHC staining of CCR6+ cells in the control group and IMQ-K14 mice on the 14th day. Arrows indicate the location of the CCR6+ cells. (c) IHC staining of CD11c+ cells in the control group and IMQ-K14 mice on the 14th day. Arrows indicate the location of the CD11c+ cells. CH: 8-week-old K14-VEGF mice; IV15: IMQ-K14 14 days.
Fig 4.
Inflammatory changes on days 8–14 in the IMQ-K14 mice.
(a) Changes in ear thickness. n = 6 (b) mRNA level changes of psoriasis-related cytokines, n = 6. (c) Protein level changes of IL-17 and IL-23, n = 3.